JP Morgan has issued a report maintaining a Neutral Rating on Johnson & Johnson JNJ.
According to the report, "J&J reported solid 2Q results yesterday morning. Sales of $16.597B (+8.3% reported, +2.6% cc, +2.0% organic) were $363M (+240bp) ahead of the Street, owing to better than expected FX (+100bp) and inventory stocking for Remicade and Concerta (+110bp)."
JNJ has a $69 Price Target and closed at $66.72 a share yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in